Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivaracetam monotherapy in childhood or juvenile absence epilepsy
2023-510428-55-00Phase 3Completed
- Sponsor
- UCB
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in childhood absence epilepsy (CAE) and juvenile absence epilepsy (JAE) comparing Brivaracetam with Placebo (2 arms). Primary endpoint: Absence seizure freedom at Day 14 by ambulatory EEG. Started May 2024; status: completed.
02
Drugs
brivaracetam
03
Conditions
childhood absence epilepsy (CAE)juvenile absence epilepsy (JAE)
Beyond the preview
Go deeper on 2023-510428-55-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510428-55-00.